



# Omico's Impact Scorecard

The data that matters: extending  
lives, building national capabilities  
and fuelling our economy



Omico.

# Australians with incurable cancers can't wait

Omico has proven that precision oncology works and has built the evidence, partnerships and infrastructure to make it accessible, effective and equitable for those who can benefit. The foundation is in place now to embed it into mainstream cancer care across Australia.

Omico offers Australians with incurable cancers access to cutting-edge precision oncology, matching them to personalised cancer treatment based on the molecular profile of their cancer.

Precision oncology uses molecular profiling through advanced tests like comprehensive genomic profiling (CGP), whole genome sequencing (WGS) or immunohistochemistry (IHC), to identify unique changes (known as biomarkers) in a person's cancer cells that drive its growth. This information is used to match the person to the precision treatment most likely to work for them, targeted specifically to the biomarkers in their cancer.



# Better outcomes for those who need them most<sup>1</sup>



A total of 31,470 referrals from 1,453 clinicians

# 27,587

## have enrolled in Omico's programs\*, since 2016

Including more than 16,200 patients who have accessed ProSPeCT since March 2023, highlighting the growing demand for precision oncology

## Equitable access

**36%** enrolments are from remote, rural and regional Australia

**>2%** identify as Indigenous

## Of the 20,365


people who underwent free CGP:

**69%** received a treatment recommendation, and of these:

**17%** enrolled in a clinical trial (2,351)

**3.3%** received matched therapy outside a trial (470)

## Identify actionable biomarkers, extend lives



(37.5%) participants in MoST & CaSP had a biomarker matching to a treatment that could extend life

Patients who received matched therapy

# Lived up to 50% longer

from 14 to 21 months

In some cases, survival more than doubled<sup>2</sup>



# Driving investment, growth and savings

Launched in March 2023, PrOSPeCT is Australia's largest cancer and genomics initiative:

 Investment & growth realised

## \$200M+


foreign investment from industry-sponsored cancer clinical trials

## 91

industry-sponsored trials across all states and territories - 16 would not have come to Australia without Omico

## \$84.9M+ growth

in Australian investment (R&D, equipment, technology, exports)


 Healthcare savings secured

## \$60M+

Estimated out-of-pocket costs avoided by patients receiving free CGP



**Reduced PBS expenditure** through patients accessing clinical trials

 Jobs & skills created

## 1,540+ jobs<sup>3</sup>

created (direct + indirect)

- 258 highly skilled roles in medicine & science
- 1,290 indirect jobs across health, pathology & pharmacy



## 39 traineeships

traineeships boosting regional & Indigenous capabilities

- 69% in regional Australia

# Omico's national clinical trial network

Enables Australia's growth as a global cancer research hub



**80 cancer treatment centres**

networked across all states and territories, 27 in regional Australia



**7 NATA-accredited labs**

previously offshore, now established in Australia to perform molecular profiling



**118 clinical trials**

supported in Australia



Omico real-world data shows access to clinical trials improves quality of life – patients are accessing trials closer to home, reducing travel burden and increasing equity.

# Leading with science and innovation

## Real-world data


Omico is gathering data to drive **new cancer discoveries** and **clinical insights**:

**19,000+** patient records and growing

**10,000+** records linked to PBS/MBS

**135,200+** biofractions stored at the NSW BioBank from 10,500+ people

## Leadership & knowledge



**50+** scientific presentations annually



**144** high-impact publications

Providing national and global **leadership** in precision oncology **policy** and **education** through professional and community engagement

# Recognised globally, creating value nationally

A proven, sustainable model. Now ready to be mainstreamed.

Recognised as a global benchmark in precision oncology, Omico has proven that its model is **viable, sustainable and scalable**.

It's time for the next step to future-proof cancer care. Starting with Australians with rare cancers, Omico has set a clear path to embed precision oncology into everyday care for those who need it most.

<sup>1</sup>Omico data on file. Data updated 30th September 2025.

<sup>2</sup>Genomic therapy matching in rare and refractory cancers: Updated results from a retrospective cohort study in the Molecular Screening and Therapeutic (MoST) program. (2023) FPY Lin, S Thavaneswaran, CE Napier, JP Grady, M Kansara et al. Journal of Clinical Oncology 41 (16\_suppl), 1540-1540 presented at ASCO 2023

<sup>3</sup>Public-private partnerships (PPPs) in healthcare: Lessons from the ProSPeCT model. [healthcaretransformers.com/healthcare-business/strategy-and-operations/ppps-in-healthcare-lessons-from-prospect/?\\_thumbnail\\_id=9398](https://healthcaretransformers.com/healthcare-business/strategy-and-operations/ppps-in-healthcare-lessons-from-prospect/?_thumbnail_id=9398)

\*Omico Programs:

RiSC: Understanding more about the genetic variants that contribute to inherited cancers and assess health-related costs.

SMOC+: Investigating surveillance for people at high-risk of multi-organ cancer, using whole-body MRI.

MoST: Molecular Screening and Therapeutics Study

ProSPeCT: Precision Oncology Screening Platform Enabling Clinical Trials, for people with advanced, incurable or poor prognosis cancers to identify potential matches to clinical trials with new targeted therapies.

**It's time to mainstream  
precision oncology.  
Together we can make  
world-class cancer care  
for all a reality.**



1800 954 350



[contact@omico.org.au](mailto:contact@omico.org.au)



[omico.com.au](http://omico.com.au)